Industry observers’ consensus sales forecasts have MAbs as making up five of the top ten selling drugs in 2014 – four of them in the top six. Furthermore, global antibody sales are expected to reach $58bn in 2014.
– Source: Thomson Reuters
With more than 80 years of experience in the biopharmaceutical industry, NNE Pharmaplan has followed the development from the early beginning and has built specialist knowledge within the area as well as a wide portfolio of MAb-related services.
Visit our MAb universe to read more about the characteristics and developments of the global MAb market and learn about our offerings and experience within the area.